The hydride generation technique was used to determination of germanium in the presence of L-cysteine.The GeH4 was absorbed and coloured by a mixed solution of 2-(5-NO2-2-pyridylazo)-5-diethylaminophenyl(5-NO2-PADAP),NaClO and (CH2)6NH+.The maximum absorption of the colour complex was at 564nm.Its apparent molar absorption coefficient was 1.84×105L·mol-1·cm-1.Beer＇s law was obeyed for 0～500μg/L germanium.The recoveries of spiked samples were in the range of 89%～97%,while the relative standard deviation was less than 6.3%.This method is sensitive,simple and reproducible.The method has been applied to the determination of Ge in the chinese medicine with satisfactory result.

Objective To investigate the efficacy and safety of different preoperative indwelling time of double J tube in the treatment of upper urinary tract calculus by transurethral flexible ureteroscopic lithotripsy(FURL).Methods 135 patients with upper urinary tract calculus who underwent transurethral FURL treatment were selected and divided into group A(1 week retention),group B(2 weeks retention)and group C(1 month retention)with 45 cases each according to the time of indentation of double J tubes.The efficacy and safety of FURL treatment in three groups were compared.Results There were no significant differences in operation time,intraoperative blood loss,postoperative hospital stay,stone removal time,success rate of channel sheath implantation at one time and stone clearance rate at one month after operation among the three groups(P>0.05).The urinary tract infection,irritation sign of bladder and gross hematuria in group A were significantly lower than those of group B and group C(P<0.05).There were no significant differences in fever and ureteral wall injury among the three groups(P>0.05).Conclusion In the treatment of upper urinary tract calculus by tranurethral FURL,the double J tube can be implanted for 1 week before operation to achieve ideal surgical treatment effect and reduce the risk of surgical complications.

ObjectiveTo investigate the characteristics of mitochondrial translational initiation factor 2 （MTIF2） gene methylation and its association with the development and progression of hepatocellular carcinoma （HCC）. MethodsMethSurv and EWAS Data Hub were used to perform the standardized analysis and the cluster analysis of MTIF2 methylation samples， including survival curve analysis， methylation signature analysis， the association of tumor signaling pathways， and a comparative analysis based on pan-cancer database. The independent-samples t test was used for comparison between two groups； a one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test was used for further comparison between two groups. The Cox proportional hazards model was used to perform the univariate and multivariate survival analyses of methylation level at the CpG site. The Kaplan-Meier method was used to investigate the survival differences between the patients with low methylation level and those with high methylation level， and the Log-likelihood ratio method was used for survival difference analysis. ResultsGlobal clustering of MTIF2 methylation showed that there was no significant difference in MTIF2 gene methylation level between different races， ethnicities， BMI levels， and ages. The Kaplan-Meier survival curve analysis showed that the patients with N-Shore hypermethylation of the MTIF2 gene had a significantly better prognosis than those with hypomethylation （hazard ratio ［HR］=0.492， P<0.001）， while there was no significant difference in survival rate between the patients with different CpG island and S-Shore methylation levels （P>0.05）. The methylation profile of the MTIF2 gene based on different ages， sexes， BMI levels， races， ethnicities， and clinical stages showed that the N-Shore and CpG island methylation levels of the MTIF2 gene decreased with the increase in age， and the Caucasian population had significantly lower N-Shore methylation levels of the MTIF2 gene than the Asian population （P<0.05）； the patients with clinical stage Ⅳ had significantly lower N-Shore and CpG island methylation levels of the MTIF2 gene than those with stage Ⅰ/Ⅱ （P<0.05）. Clinical validation showed that the patients with stage Ⅲ/Ⅳ HCC had a significantly lower methylation level of the MTIF2 gene than those with stage Ⅰ/Ⅱ HCC and the normal population （P<0.05）. ConclusionN-Shore hypomethylation of the MTIF2 gene is a risk factor for the development and progression of HCC.